Author

T. D. Dubash

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

B. S. Wittner· 2 shared D. A. Haber· 2 shared D. T. Ting· 2 shared S. Maheswaran· 2 shared W. Haas· 2 shared A. Bardia· 1 shared A. Szabolcs· 1 shared B. Chirn· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. S. Wittner

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CDKN1B (p27kip1) enhances drug tolerant persister CTCs by restricting polyploidy following mitotic inhibitors.

E. Horwitz, T. D. Dubash, A. Szabolcs, B. S. Wittner, J. Kreuzer, R. Morris, A. Bardia, B. Chirn, D. Wiley, D. Che, H. C. Russel, X. I. H. Lopez, D. B. Fox, E. Antmen, D. T. Ting, , D. A. Haber

This study identifies CDKN1B as a regulator of drug-tolerant persister CTCs by preventing polyploidy after mitotic inhibitor treatment in breast cancer.

bioRxiv · Feb 20, 2024 · PreprintCancer Biology

Single cell proteomics of tumor compartments identifies differential kinase activities defining sensitivity to mTOR-PI3-kinase inhibition

N. M. Karabacak, Y. Zheng, T. D. Dubash, R. Burr, D. S. Micalizzi, B. S. Wittner, D. F. Wiley, V. Comaills, E. Emmons, K. Niederhoffer, U. Ho, L. Nieman, W. Haas, S. L. Stott, D. T. Ting, , S. Maheswaran

The paper uses single cell proteomics to identify kinase activity differences in tumor compartments, showing how they affect sensitivity to mTOR-PI3K inhibition.

bioRxiv · Jan 6, 2021 · PreprintCancer Biology